Novartis Sites New Vaccines Headquarters Outside Boston
Pharmaceuticals giant Novartis (Basel, Switzerland, www.novartis.com) has chosen Cambridge, MA, as the global headquarters for its vaccines and diagnostics division.
Pharmaceuticals giant Novartis (Basel, Switzerland, www.novartis.com) has chosen Cambridge, MA, as the global headquarters for its vaccines and diagnostics division. The site is planned to be fully staffed by the second half of 2007 and will be located near the Cambridge-based Novartis Institutes for BioMedical Research, the company’s global pharmaceuticals research headquarters.
The new Novartis Vaccines and Diagnostics site will have approximately 250 employees in positions such as research, development, marketing, human resources, IT, finance, and general management. The majority of the division's leadership team also will be based in Cambridge.
As part of a restructuring of its vaccines business, Novartis is attempting to create a global network of vaccine manufacturing sites and implementing programs to improve reliability and increase supply of influence vaccines. The second-largest supplier of flu vaccines in the US, Novartis expects to complete shipments of more than 30 million influenza vaccines for the current seasonal flu period in the US.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
